Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.
Epistemonikos ID: 2a3a7ad12f64b6f346c1739a396483f8316a625e
First added on: May 09, 2024